Elective double mastectomy seen as 'only option' after station owner tests positive to breast cancer gene Shorter Breast Cancer Treatment With Herceptin May Be Just as Effective Shorter trastuzumab treatment for HER2+ breast cancer can be as effective, with fewer cardiac side-effects Good News on Early Breast Cancer: Herceptin Treatment Can Be Shortened Shorter breast cancer treatment could hurt providers' bottom line

Elective double mastectomy seen as 'only option' after station owner tests positive to breast cancer gene

For rural woman Bree Wakefield, an elective double mastectomy was her only guarantee of being there for her husband and children, after testing positive to the 'breast cancer gene'.

The initial diagnosis of cancer is frightening. Eileen was told not to worry. Lead study author Helena Earl , professor of clinical cancer medicine at the University of Cambridge, highlighted the results on a May 16 conference call with reporters. Many women diagnosed with breast cancer are prescribed aromatase inhibitors after they complete their treatment in order to ward off recurrences. Less well known are the subtle side effects ...

Brawley said. “The longer you give it, the likelier they are to get it. After four years, the disease-free survival rate was 89.4 percent in those treated for six months, and 89.8 percent in the 12-month group. Many health systems look to their oncology service lines as a central part of their business models. This undated image made available by F. Earl has consulted for Herceptin's maker, Roche.

According to data presented in their article , for every 10,000 women in their 40s screened annually for 10 years, 32 women will die despite being screened and just three deaths will be averted. This is not intended to be a forum for definitive discussions about medicine or science. Following surgery for early HER2-positive breast cancer, investigators at 152 sites in England randomized 4,088 patients to receive 6 or 12 months of trastuzumab.

Shorter Breast Cancer Treatment With Herceptin May Be Just as Effective

New research suggests that six months of drug treatment could work as well as 12 months, with fewer side effects.

Wellness inspired. Some tumors will eventually require removal, but others will not grow, spread or threaten the patient’s life or health. So it’s a wonderful thing if you can give it for a shorter time.” In the United States, 266,000 new cases of invasive breast cancer are expected in 2018, and nearly 41,000 deaths. Disease-free survival means they had no signs of breast cancer, and the lack of difference between the two groups suggests that their overall survival should be equal as well, Dr.

Hoffmann-La Roche shows a vial of the company's Herceptin medication. The company had no role in the study. "There's no reason to not immediately change practice. You might want to skip this mammography primer from U.S. More than half of those women — 6,130 — will get a false positive result and 700 will get an unnecessary biopsy. If your comment doesn't adhere to these policies, we won't post it.

But what happens to patients who live in rural areas, the ones who live hours from the nearest doctor or hundreds of kilometres from life-saving treatment? Is this a wolf? Herceptin has proved to be effective in the treatment of women whose cancer is HER2 positive. Breast Cancer Top Breast Cancer News of the Week: Should you Worry That The Pill Increases Breast Cancer Risk? Wellness enabled. The Herceptin study was paid for by the British government.

Shorter trastuzumab treatment for HER2+ breast cancer can be as effective, with fewer cardiac side-effects

Providers are also targeting partners that could bolster their cancer programs. Posted: May. The findings are persuasive," said Dr. Mary Chris Jaklevic is a reporter-editor at HealthNewsReview.org. The U.S. Shed light, not just heat. Earl disclosed relevant relationships with Celgene, Pfizer, Roche, AstraZeneca, Daiichi Sankyo, Amgen and Sanofi. Bree Wakefield lives on Banoon Station in remote New South Wales.

The drug was first approved by the Food and Drug Administration (FDA) in 1998 for the treatment of metastatic breast cancer. It was hard to escape the flurry of news related to the pill and breast cancer last week. Everyday Health is among the federally registered trademarks of Ziff Davis, LLC and may not be used by third parties without explicit permission. Johnson said that although drug companies finance many studies, they are not eager to pay for research that may decrease use of their products.

Good News on Early Breast Cancer: Herceptin Treatment Can Be Shortened

A large, new study shows that the treatment regimen, typically recommended for a year, can be just as effective at 6 months, reducing serious side effects and costs.

Radiation increases the risk for cancer, particularly for women who have BRCA gene mutations that impair the body’s ability to fix breaks in DNA. Facts, challenges, disagreements, corrections — those are all fine. At MedPage Today, we are committed to ensuring that individuals with disabilities can access all of the content offered by MedPage Today through our website and other properties. Nine years ago, she had genetic testing for the BRCA breast cancer gene after her aunty and father both tested positive for the genetic mutation.

In the trial, 8 percent of women in the 12-month group dropped out of the study due to heart problems, compared with only 4 percent in the six-month group. What was all the fuss about? Credit Dr P. Brawley agreed, saying: “When drug companies do research, they’re interested in gaining knowledge such that they can make money for their shareholders. The findings do not apply to women with more advanced disease that has spread, Stage 4.

Part of what attracted Atrium Health, formerly Carolinas HealthCare System, to Navicent Health is the opportunity to grow its oncology network , executives said. The study was done in the United Kingdom and funded by UK government grants. Most of Herceptin's cancer-fighting benefit seems to come in the early months of use, he said. Take a recent U.S. Keating also noted that radiologists — two of whom are quoted in the U.S.

Shorter breast cancer treatment could hurt providers' bottom line

Women who use the breast cancer drug Herceptin for six months did just as well as those who took it for a year, according to a new study that could ultimately benefit value-based providers and harm those still based on fee-for-service models.

Shorter Breast Cancer Treatment With Herceptin May Be Just as Effective New research suggests that six months of drug treatment could work as well as 12 months, with fewer side effects. That study concluded that 12 months of treatment should remain the standard of care. Breast Cancer Tips for Tackling Chemo Brain Forgetting details? Marazzi/Science Source By Denise Grady May 16, 2018 Over the past 20 years, hundreds of thousands of women with breast cancer have taken the drug Herceptin, typically for a year or more.

Those patients need a longer course of treatment, Dr. To change that standard, researchers had to produce evidence that it could be safely done. Atrium spent $150 million to double the size of its Levine Cancer Institute and expects a 10% return on that investment. Results were released Wednesday by the American Society of Clinical Oncology and will be presented at the group's meeting next month. Others said that because so few women have died or relapsed after being treated with the drug, longer followup may be needed to make sure the findings hold up before guidelines should be changed.

While she’s won fame for treating Angelina Jolie and Sheryl Crow, Funk doesn’t exactly come across as a stickler for evidence-based practices. Retweet on Twitter HealthNewsReview.org Retweeted Dr. Women who carry the BRCA gene, are at an increased risk of developing breast cancer, but it does not mean that those with the gene will definitely get breast cancer. Sign Up for Our Cancer Care and Prevention Newsletter Thanks for signing up!

Test of Herceptin Finds Briefer Treatment Can Work, With Fewer Side Effects

Earl said. Earl’s study is the first step in that direction. That being said, women who are HER2-positive and take Herceptin or related drugs represent only about one-fifth of breast cancer patients, Conway said. It was later approved for treatment of those cancers in earlier stages, too, based on studies that had tested it in patients for 12 months. Doctors also want to see results published, and to study them to see if certain groups of women need longer treatment.

She’s been promoting a newly published book with a smoothie recipe that she says contains “cancer-kicking” compounds. Lot’s of them. The Breast Cancer Network of Australia provide support for families who are concerned about their own risk of carrying the BRCA1 or BRCA2 breast cancer gene mutation. You might also like these other newsletters: Sign up for more FREE Everyday Health newsletters .

Having a hard time managing what used to be easy tasks? The shorter regimen also saved money. But Dr. She said the findings would undergo “rigorous scientific scrutiny” by other researchers and be published in a peer-reviewed journal. Follow @NYTHealth on Twitter. | Sign up for the Science Times newsletter. Still, there are broader implications as more studies come to fruition. That guess, that the drug should be taken for a year, became the standard of care.

Six months of Herceptin could be as effective as 12 months for some women with HER2 positive breast cancer

Saying all women should get screened starting at age 40, as the U.S. In a weird coincidence, the ACS recently introduced its own smoothie, but the organization doesn’t claim it can prevent cancer. Thank you for joining the HealthNewsReview.org mailing list. They provide support for families wishing to have genetic testing and for those who need an early detection plan. Please enter a valid email address Sign up Oops!

It could be chemo brain — and there are ways to cope. A yearlong course of the drug costs $76,700. The new study is the first to show that women with early-stage disease can safely cut back on Herceptin, Dr. Earl said. “This could be absolutely practice-changing for a lot of patients,” said Dr. A version of this article appears in print on , on Page A 12 of the New York edition with the headline: Breast Cancer Drug Herceptin’s Regimen Can Be Much Shorter, Study Shows .

But the drug can hurt the heart's ability to pump. In December, a copycat competitor known as a biosimilar was approved in the U.S. and already is used in some other countries. Recent years have brought increasing recognition of the pitfalls of mammography. Marketing misfire on 'spa-like' 3D mammograms: Comfort appeal distracts from real concerns on screening, experts say There’s a reason mammograms are the perfect fodder for female comedians.

Shorter drug treatment OK for many breast cancer patients

Many women with a common and aggressive form of breast cancer that is treated with Herceptin can get by with six months of the drug.

Breast Cancer Breast Cancer: One Type of Insulin May Increase Your Risk The benefits of long-acting insulin may outweigh the risks. Breast Cancer Is There Beauty During Breast Cancer Treatment? Bruce E. Helena Earl, its first author, at the University of Cambridge in Britain, said in an email. “Here we are asking the question whether less is more,” she said. Jennifer Litton, an associate professor of breast medical oncology at MD Anderson Cancer Center in Houston.

It could also lower out-of-pocket costs and improve patient satisfaction, which are important metrics in new payment models, she said. That often eases if treatment is stopped but the damage can be permanent and lead to heart failure. Jennifer Litton, a breast specialist at MD Anderson Cancer Center in Houston, said Herceptin was a true breakthrough, but scaling back treatment whenever possible is just as important to patients.

Prostate cancer screening: massive study gets minimal coverage. You may unsubscribe via the link found at the bottom of every email. At the end of the day Bree was only hoping to get an early diagnosis, it was not going to prevent or reduce her risk of getting breast cancer. Please select a newsletter We respect your privacy . A little time before the ... Cancer treatments can be physically and emotionally taxing, and can also alter your appearance.

Turning 40? You might want to skip this mammography primer from US News

A recent U.S. News feature entitled "12 Things to Know Before Your First Mammogram" could have provided women with balanced information on the benefits and harms of mammography. Instead, it conveyed a misleading and one-sided message that annual screening starting at age 40 "saves the most lives."

A widely used breast cancer drug is as effective over a shorter treatment cycle, according to new research . It will likely have to come from providers and the National Institute of Health, Shanware said. Some studies tested shorter use, but results conflicted. Herceptin's developer, Genentech, now part of Roche, said in a statement that the new study must be viewed along with several smaller previous ones that found one year to be best.

We Welcome Comments. Note that this study was published as an abstract and will be presented at a conference. The difficulty in accessing the necessary diagnostic services and cancer treatment services in regional areas is an ongoing challenge. Herceptin has proved to be highly effective in treating HER2-positive breast cancer. Breast Cancer Item Number One on New Year’s Resolution List: Be Your Own Health Advocate Breast cancer survivors share how to take control of your health in the new year.

Johnson said. About 15 percent of women with early breast cancer have tumors that respond to Herceptin, also called trastuzumab. She had a patient like that whom she had worried about. “Now I don’t feel bad,” Dr. While shorter treatments expose patients to fewer side effects and reduce cost, they could also have a significant impact on a profitable stream of hospital revenue. Alex Kacik is the hospital operations reporter for Modern Healthcare in Chicago.

Six Months of Trastuzumab Equal to 12 in Breast Ca

Similar outcomes and less cardiotoxicity, but more research needed

But please note: We will delete comments left by anyone who doesn’t leave an actual first and last name and an actual email address . In response to a question, Earl declined to say the results made a definitive case for a new standard of care for early HER2-positive breast cancer. The disparity between regional and metropolitan cancer survival outcomes is nothing new. A shorter course of treatment would have major implications for patients in terms of cost and risk of side effects.

Breast Cancer Scalp Cooling Caps Can Minimize Hair Loss During Chemotherapy Hair loss is one of the biggest concerns for women undergoing chemotherapy for breast cancer. The study has not yet been published in a medical journal, and some experts reserved judgment until the data have been peer-reviewed. Such tumors are particularly aggressive, because they have high levels of a protein called HER2, which promotes cancer growth.

Herceptin costs about $70,000 for a full year of weekly infusions that treat early-stage breast cancer. Aside from hospital operations, he covers supply chain, legal and finance. After four years, about 90 percent of both groups were alive without signs of the disease. Sorry, you are using an unsupported browser. A small number of women who get aggressive forms of breast cancer will die of breast cancer even if they had been getting regular mammograms.

What we're saying at the moment is that we need to have a detailed look at this group of patients," she said. "The headline result is that 6 months is as good as 12 months. Cancer support groups have been lobbying for more regionally based cancer treatment centres for years. A year of Herceptin therapy carries a price tag of more than $75,000; the drug’s potentially serious side effects include heart damage.

Study: Shorter drug treatment OK for many breast cancer patients

Now there are options to prevent it. For example, a study last year showed that many patients with colon cancer could safely shorten their course of chemotherapy from six months to three. The drug significantly increases survival in those women. The women were 23 to 82 years old, with a median age of 56. The five-year survival rate was nearly identical, and patients suffered fewer side effects, including heart problems.

Only 4 percent on the shorter treatment dropped out due to heart problems versus 8 percent of those treated for a year. "It's great news" for patients, said the study leader, Dr. This page will not display correctly. Overdiagnosis is particularly worrisome. We will also end any thread of repetitive comments. Clinical trials consistently showed a significant reduction in cancer recurrence and death in patients who received adjuvant trastuzumab for early HER2-positive breast cancer.

The PERSEPHONE trial was conducted in the United Kingdom and funded by the National Institute for Health Research , a government agency. Breast Cancer Breast Cancer: How Long on Aromatase Inhibitors Is Long Enough? Breast Cancer On Chemo Brain and Dropped Words Everybody knows that chemotherapy kills cancer cells and comes with side effects like nausea and fatigue. And a study in 2016 found that many women with early-stage breast cancer , who traditionally would have been given chemo, could safely skip it, based on tests of gene activity in their tumors.

They were followed for a median of more than five years. Bruce Johnson, president of the American Society of Clinical Oncology, which will be presenting the research at an ASCO meeting next month. The weekly magazine, websites, research and databases provide a powerful and all-encompassing industry presence. Helena Earl of the University of Cambridge in England. Spring St. It refers to cancers found through screening that would never have become life threatening but get treated anyway because doctors can’t tell whether a cancer is life-threatening or not.